Pressure Bio Q3 Revenues Rise 7 Percent on PCT Business | GenomeWeb

NEW YORK (GenomeWeb News) – Pressure BioSciences saw revenues in its third quarter climb 7 percent year over year as revenues derived from its Pressure Cycling Technology grew 10 percent, the company said today.

The South Easton, Mass.-based firm said that total revenues reached $420,762 for the three months ended Sept. 30, compared to $391,616 a year ago. Revenues from PCT products, services, and other were $327,958, compared to $297,867 a year ago, while grant revenues narrowed to $92,804 from $93,749.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.